Literature DB >> 17083564

Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts.

Kozo Masuda1, Akio Hiraki, Nobuharu Fujii, Toshiyuki Watanabe, Motoyuki Tanaka, Kosei Matsue, Yoichiro Ogama, Mamoru Ouchida, Kenji Shimizu, Kazuma Ikeda, Mitsune Tanimoto.   

Abstract

Loss or down-regulation of human leukocyte antigen (HLA) class I expression has been demonstrated in a variety of solid tumors. To date, such altered HLA expression has not been studied extensively in freshly isolated leukemic blasts. If it occurs, leukemic cells could escape T-cell surveillance as a consequence. Genotypes of nine leukemic cell lines were determined using a polymerase chain reaction for HLA classes I and II. Cells were also examined for HLA beta2-microglobulin, and allele-specific HLA protein expression using flow cytometry. Next, 44 samples of freshly isolated leukemic blasts from 43 patients with malignant hematological diseases were examined for allele-specific HLA expression using flow cytometry. Microsatellite analysis was performed to determine heterozygosity in the HLA region on chromosome 6. Genotype analysis for HLA class I together with microsatellite analysis demonstrated loss of HLA haplotype in HL-60 cells. No loss of HLA haplotype was observed in 44 samples of freshly isolated leukemic blasts. As reported previously, flow cytometric analysis rarely demonstrated loss or down-regulation of HLA expression at initial diagnosis (3/39; 7.7%); however, this was evident in two of five cases in relapse (40.0%), which contrasts with previous reports. In one patient with acute leukemia, HLA-A2 cell surface expression was present at initial diagnosis, lost at relapse, and completely restored after 48 h of culture in the presence of interferon-gamma. These results suggest loss of allele-specific HLA expression may be involved in the pathogenesis of relapse in patients with leukemia. The findings should be valuable in designing new strategies for clinical immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17083564     DOI: 10.1111/j.1349-7006.2006.00356.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  25 in total

1.  Identification of potential HLA class I and class II epitope precursors associated with heat shock protein 70 (HSPA).

Authors:  Pawel Stocki; Nicholas J Morris; Christian Preisinger; Xiao N Wang; Walter Kolch; Gabriele Multhoff; Anne M Dickinson
Journal:  Cell Stress Chaperones       Date:  2010-04-01       Impact factor: 3.667

2.  Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.

Authors:  Phuong Vo; Elaine S Jaffe; Lisa Cook; Catalina Ramos; Richard Childs
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-08-30

3.  A novel method for KIR-ligand typing by pyrosequencing to predict NK cell alloreactivity.

Authors:  Gong Yun; Jakub Tolar; Anton K Yerich; Steven G E Marsh; James Robinson; Harriet Noreen; Bruce R Blazar; Jeffrey S Miller
Journal:  Clin Immunol       Date:  2007-04-18       Impact factor: 3.969

4.  HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Blood Adv       Date:  2018-12-26

Review 5.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

6.  Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?

Authors:  A Hamdi; K Cao; L M Poon; F Aung; S Kornblau; M A Fernandez Vina; R E Champlin; S O Ciurea
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

7.  Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.

Authors:  Sara Mastaglio; Eric Wong; Travis Perera; Jane Ripley; Piers Blombery; Mark J Smyth; Rachel Koldej; David Ritchie
Journal:  Blood Adv       Date:  2018-02-27

Review 8.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

9.  IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells.

Authors:  Yuqing Shen; Mei Xia; Jianqiong Zhang; Lianhong Xu; Jin Yang; Aiqin Chen; Fengqin Miao; Soldano Ferrone; Wei Xie
Journal:  Mol Immunol       Date:  2009-05-09       Impact factor: 4.407

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.